Table 1

Clinical characteristics of the patients

Clinical variablesGroup A
(n=268)
Group B
(n=771)
Group C
(n=384)
Group D
(n=216)
p Value
Age (years)57.5±5.457.6±5.557.5±5.657.0±6.20.594
Female subjects, n (%)174 (64.9)532 (69.0)280 (72.9)141 (65.3)0.104
Smoking, n (%)38 (14.2)82 (10.6)38 (9.9)21 (9.7)0.293
Hypertension, n (%)33 (12.3)97 (12.6)39 (10.2)23 (10.6)0.617
Diabetes mellitus, n (%)14 (5.2)43 (5.6)24 (6.3)20 (9.3)0.217
Coronary artery disease, n (%)18 (6.7)45 (5.8)16 (4.2)10 (4.6)0.462
Atrial fibrillation, n (%)146 (54.5)504 (65.4)252 (65.6)128 (59.3)0.006
NYHA>II, n (%)109 (40.7)316 (41.0)189 (49.2)125 (57.9)<0.001
eGFR (mL/min/1.73 m2)89.6±26.488.0±24.388.0±26.184.2±24.50.116
Haemoglobin (g/L)137.5±14.0135.4±15.9131.3±16.8130.6±15.8<0.001
LVEF, %61.7±9.762.1±8.460.1±9.662.1±10.20.004
RV diameter, mm48.9±7.750.2±6.853.7±7.655.5±9.0<0.001
LVEDD index, mm/m²50.5±9.849.0±7.949.0±8.645.4±9.2<0.001
MR volume, cm2
 <4107 (39.9)278 (36.1)147 (38.3)104 (48.1)0.003
 4–873 (27.2)208 (27.0)82 (21.4)35 (16.2)
 >888 (32.8)285 (37.0)155 (40.4)77 (35.6)
MVA≤1.5 cm2 228 (85.1)670 (86.9)323 (84.1)194 (89.8)0.222
TR volume, cm2 1.9 (0, 3.2)4.8 (2.8, 7.4)8.3 (5.3, 11.4)10.4 (6.9, 14.3)<0.001
Aortic valve replacement107 (39.9)302 (39.2)152 (39.6)83 (38.4)0.988
CABG17 (6.3)35 (4.5)14 (3.6)10 (4.6)0.452
In-hospital death5 (1.9)18 (2.3)18 (4.7)22 (10.2)<0.001
  • CABG, coronary artery bypass grafting.; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MVA, mitral valve area; NYHA, New York Heart Association; RV, right ventricle; TR, tricuspid regurgitation.